The Association for Accessible Medicines (AAM) has released the 10th edition of its annual Generic Drug Access and Savings Report that provides an outline of the savings generated by generics and biosimilars in the past year.
The Association for Accessible Medicines (AAM) has released the 10th edition of its annual Generic Drug Access and Savings Report that provides an outline of the savings generated by generics and biosimilars in the past year.
The report, which represents data derived from IQVIA, discovered that in 2017, 9 out of every 10 prescriptions in the United States were dispensed using generic drugs. However, although branded drugs only represent about 10% of prescriptions, they account for 77% of total drug spending. Additionally, savings from generics in the United States totaled $265.1 billion in 2017 alone.
At the time the report was compiled, the FDA had approved 11 biosimilars, and the report notes that there were more than 60 additional products in development. Since then, the FDA has approved another filgrastim biosimilar, to be sold as Nivestym. “Biosimilars have the potential to improve the quality of life for American patients while at the same time saving the health system billions of dollars each year—provided that the right policies are in place to nurture a robust market,” read the AAM report.
“Anybody who cares about the US healthcare system, and all the patients who depend on it, should recognize the role that generic and biosimilar medicines play in keeping people healthy and productive,” said Chester Davis, Jr., president and CEO of AAM, in a statement.
The US healthcare system—and the rising cost of drugs—have indeed generated a great deal of attention since the announcement of the Trump administration’s blueprint to lower drug prices, and polls conducted by The Kaiser Family Health Foundation have repeatedly demonstrated that drug costs are a key issue for Americans; Kaiser has found that approximately 80% of Americans think that the cost of prescription drugs is unreasonable, and 73% believe that pharmaceutical companies are making too much profit on their products.
Americans are also having a hard time paying for their medications; Kaiser found than half of Americans are taking at least 1 prescription drug, and a quarter are taking at least 4. Although most respondents (74%) reported that they can afford their medications, among those who said that they take 4 or more drugs, 35% of uninsured people younger than 65 years said that they had skipped filling a prescription because of cost, and 26% reported cutting pills in half or missing doses to save money. Those who had an income of under $40,000 per year reported the worst compliance.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.